↓ Skip to main content

Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial

Overview of attention for article published in BMC Cancer, September 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
twitter
8 X users

Citations

dimensions_citation
106 Dimensions

Readers on

mendeley
179 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
Published in
BMC Cancer, September 2014
DOI 10.1186/1471-2407-14-671
Pubmed ID
Authors

Karel Decaestecker, Gert De Meerleer, Filip Ameye, Valerie Fonteyne, Bieke Lambert, Steven Joniau, Louke Delrue, Ignace Billiet, Wim Duthoy, Sarah Junius, Wouter Huysse, Nicolaas Lumen, Piet Ost

Abstract

Metastases-directed therapy (MDT) with surgery or stereotactic body radiotherapy (SBRT) is emerging as a new treatment option for prostate cancer (PCa) patients with a limited number of metastases (≤3) at recurrence - so called "oligometastases". One of the goals of this approach is to delay the start of palliative androgen deprivation therapy (ADT), with its negative impact on quality of life. However, the lack of a control group, selection bias and the use of adjuvant androgen deprivation therapy prevent strong conclusions from published studies.The aim of this multicenter randomized phase II trial is to assess the impact of MTD on the start of palliative ADT compared to patients undergoing active surveillance.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 <1%
Germany 1 <1%
Brazil 1 <1%
Unknown 176 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 16%
Student > Ph. D. Student 19 11%
Student > Master 19 11%
Student > Bachelor 17 9%
Other 14 8%
Other 44 25%
Unknown 37 21%
Readers by discipline Count As %
Medicine and Dentistry 94 53%
Nursing and Health Professions 8 4%
Agricultural and Biological Sciences 4 2%
Immunology and Microbiology 3 2%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 15 8%
Unknown 52 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2022.
All research outputs
#2,320,030
of 22,653,392 outputs
Outputs from BMC Cancer
#434
of 8,237 outputs
Outputs of similar age
#26,805
of 246,315 outputs
Outputs of similar age from BMC Cancer
#8
of 154 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,237 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,315 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 154 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.